Nur Sener
Overview
Explore the profile of Nur Sener including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olmez O, Bilici A, Er O, Bisgin A, Sevinc A, Akman T, et al.
Jpn J Clin Oncol
. 2024 Jan;
54(5):562-568.
PMID: 38271177
Objective: The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced...
2.
Sener N, Yakupoglu A
Medicine (Baltimore)
. 2023 Sep;
102(35):e34674.
PMID: 37657033
Hepatocellular carcinoma (HCC) with portal vein tumor thrombus is considered an advanced stage disease. Non-surgical local and systemic therapies are the only treatment options available. To analyze the survival and...
3.
Aydin D, Sendur M, Kefeli U, Bala Ustaalioglu B, Aydin O, Yildirim E, et al.
Clin Colorectal Cancer
. 2016 Jun;
16(1):78-83.
PMID: 27247089
Background: Small bowel adenocarcinomas (SBAs) are rarely seen tumors. Data regarding the use of chemotherapy together with bevacizumab in patients with advanced SBA are lacking. The aim of this study...
4.
Yildirim M, Kefeli U, Aydin D, Sener N, Gumus M
Tumour Biol
. 2016 Apr;
37(9):11903-11907.
PMID: 27067437
Netrin-1 is found to be elevated and purposive as a diagnostic biomarker in many human cancers. We evaluated serum netrin-1 concentrations in patients with advanced non-small cell lung cancer compared...
5.
Uyeturk U, Oksuzoglu B, Akman T, Turker I, Sener N, Tastekin D, et al.
Med Oncol
. 2014 Mar;
31(4):929.
PMID: 24659267
Primary metastatic breast cancer (PMBC) comprises 3-10% of all BCs. PMBC is a heterogeneous disease. To date, little is known about the tumor characteristics, treatment results, and overall survival (OS)...
6.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, et al.
Onkologie
. 2013 Oct;
36(10):554-8.
PMID: 24107908
Background: The objective of this study was to identify prognostic factors affecting the recurrence-free survival (RFS) in patients who received a 52-week trastuzumab therapy for HER2-positive early stage breast cancer...
7.
Kaplan M, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, et al.
Breast Cancer
. 2013 Jan;
21(6):677-83.
PMID: 23335064
Purpose: In this study, we investigated the effect of lapatinib plus capecitabine treatment in HER2-positive breast cancer patients with brain metastasis. Methods: Of 405 metastatic breast cancer patients with brain...
8.
Kefeli U, Yildirim M, Aydin D, Madenci O, Yasar N, Sener N, et al.
Biomarkers
. 2012 Aug;
17(7):663-7.
PMID: 22889408
Context: Netrin-1 is found to be elevated and usable as a diagnostic biomarker in many human cancers. Objectives: We evaluated serum Netrin-1 concentrations in patients with advanced gastric cancer compared...
9.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Oksuzoglu B, et al.
J Cancer Res Clin Oncol
. 2012 Aug;
138(12):2145-51.
PMID: 22878681
Purposes: Trastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the...
10.
Namal E, Sener N, Ulas T, Akcali Z, Oztekin E, Borlu F
Anadolu Kardiyol Derg
. 2011 Nov;
11(8):703-10.
PMID: 22088858
Objective: The aim of our study was to evaluate the effects of two different statins and a statin/ezetimibe combination on high sensitive C-reactive protein (hsCRP) values, which were given at...